PMID: 7539040Jun 1, 1995Paper

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

The Journal of Experimental Medicine
B FiskC G Ioannides

Abstract

Synthetic peptide analogues of sequences in the HER-2 protooncogene (HER-2) were selected based on the presence of HLA-A2.1 anchor motifs to identify the epitopes on HER-2 recognized by ovarian tumor-reactive CTL. 19 synthetic peptides were evaluated for recognition by four HLA-A2 ovarian-specific cytotoxic T lymphocyte (CTL) lines obtained from leukocytes associated with ovarian tumors. The nonapeptide E75 (HER-2, 369-377:KIFGSLAFL) was efficient in sensitizing T2 cells for lysis by all four CTL lines. This peptide was specifically recognized by cloned CD8+ CTL isolated from one of the ovarian-specific CTL lines. E75-pulsed T2 cells inhibited lysis by the same CTL clone of both an HLA-A2+ HER-2high ovarian tumor and a HER-2high cloned ovarian tumor line transfected with HLA-A2, suggesting that this or a structurally similar epitope may be specifically recognized by these CTL on ovarian tumors. Several other HER-2 peptides were recognized preferentially by one or two CTL lines, suggesting that both common and private HER-2 epitopes may be immunogenic in patients with ovarian tumors. Since HER-2 is a self-antigen, these peptides may be useful for understanding mechanisms of tumor recognition by T cells, immunological tolerance t...Continue Reading

References

Dec 1, 1992·The Journal of Experimental Medicine·B CatipovićJ P Schneck
Jan 1, 1992·Molecular Carcinogenesis·C G IoannidesC A O'Brian
Aug 19, 1991·International Journal of Cancer. Journal International Du Cancer·F RilkeA Testori
Sep 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·D L BarndO J Finn
Jul 5, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y KawakamiS A Rosenberg
Aug 4, 1993·Journal of the National Cancer Institute·G A NiehansD T Kiang

❮ Previous
Next ❯

Citations

Jul 29, 1996·International Journal of Cancer. Journal International Du Cancer·V RussoC Traversari
Mar 12, 1998·International Journal of Cancer. Journal International Du Cancer·C M BöhmC Hanski
Oct 1, 1998·International Journal of Cancer. Journal International Du Cancer·H OkadaM E Bozik
Oct 1, 1998·International Journal of Cancer. Journal International Du Cancer·K KonoR Kiessling
Feb 6, 1999·International Journal of Cancer. Journal International Du Cancer·I NukayaI Kato
Jan 7, 2000·Journal of Cellular Physiology·S MénardS M Pupa
Nov 1, 1996·Seminars in Surgical Oncology·C L Slingluff
Oct 18, 2002·Biopolymers·Roshni SundaramPravin T P Kaumaya
Jan 17, 2002·Genes, Chromosomes & Cancer·Eckart Meese, Nicole Comtesse
Feb 22, 2002·International Journal of Cancer. Journal International Du Cancer·Koji KonoYoshiro Matsumoto
Apr 12, 2002·International Journal of Cancer. Journal International Du Cancer·Constantin N BaxevanisMichael Papamichail
Jan 1, 1996·Springer Seminars in Immunopathology·V H Engelhard
Jan 1, 1996·Springer Seminars in Immunopathology·P Romero
Aug 24, 1999·Medical Oncology·P JantscheffC Rochlitz
Jan 1, 1997·Immunologic Research·Y Kawakami, S A Rosenberg
Jan 1, 1996·Immunologic Research·Y Kawakami, S A Rosenberg
Aug 12, 2010·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Peter MeyerhuberHelga Bernhard
Nov 24, 2004·Cancer Immunology, Immunotherapy : CII·Mauro Provinciali, Arianna Smorlesi
Aug 17, 2004·Cancer Immunology, Immunotherapy : CII·Luisa NovellinoGiorgio Parmiani
Dec 23, 2004·Cancer Immunology, Immunotherapy : CII·Jasmin DittmannCécile Gouttefangeas
Sep 10, 2005·Cancer Immunology, Immunotherapy : CII·Barbara L F KaplanMichael I Nishimura
May 3, 2005·Cancer Immunology, Immunotherapy : CII·J WiereckyP Brossart
Jun 11, 2005·Cancer Immunology, Immunotherapy : CII·Constantin N BaxevanisMichael Papamichail
Jan 26, 2006·Cancer Immunology, Immunotherapy : CII·Kousaku MimuraHideki Fujii
Jun 21, 2007·Cancer Immunology, Immunotherapy : CII·Tiffany M CarrKevin T Hogan
Jul 25, 2007·Cancer Immunology, Immunotherapy : CII·Helga BernhardChristian Peschel
Jun 10, 2008·Cancer Immunology, Immunotherapy : CII·Elizabeth A MittendorfGeorge E Peoples
Jun 10, 2010·Cancer Immunology, Immunotherapy : CII·Maha Zohra LadjemiIsabelle Navarro-Teulon
Apr 6, 1999·Pharmacology & Therapeutics·B R MinevM S Mitchell
Jun 1, 1997·Immunology Today·T BoonB Van den Eynde

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.